BME:PANG

Stock Analysis Report

Executive Summary

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Share Price & News

How has Pangaea Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

PANG

-0.1%

ES Life Sciences

0.5%

ES Market


1 Year Return

-28.0%

PANG

7.2%

ES Life Sciences

4.6%

ES Market

Return vs Industry: PANG underperformed the Spanish Life Sciences industry which returned 7.2% over the past year.

Return vs Market: PANG underperformed the Spanish Market which returned 4.6% over the past year.


Shareholder returns

PANGIndustryMarket
7 Day0%-0.1%0.5%
30 Day-6.1%-4.3%1.6%
90 Day-12.4%-5.1%0.4%
1 Year-21.3%-28.0%8.1%7.2%8.1%4.6%
3 Yearn/a63.4%55.3%13.6%3.1%
5 Yearn/a227.2%202.0%9.0%-11.5%

Price Volatility Vs. Market

How volatile is Pangaea Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pangaea Oncology undervalued compared to its fair value and its price relative to the market?

2.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate PANG's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PANG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PANG is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: PANG is unprofitable, so we can't compare its PE Ratio to the Spanish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PANG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PANG is good value based on its PB Ratio (2.6x) compared to the XE Life Sciences industry average (3.5x).


Next Steps

Future Growth

How is Pangaea Oncology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pangaea Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pangaea Oncology performed over the past 5 years?

-41.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PANG is unprofitable, and losses have increased over the past 5 years at a rate of -41.3% per year.

Accelerating Growth: Unable to compare PANG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PANG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (14%).


Return on Equity

High ROE: PANG has a negative Return on Equity (-14.54%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PANG is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PANG is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Pangaea Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: PANG's short term assets (€5.5M) exceeds its short term liabilities (€5.0M)

Long Term Liabilities: PANG's short term assets (5.5M) do not cover its long term liabilities (6.8M)


Debt to Equity History and Analysis

Debt Level: PANG's debt to equity ratio (55.2%) is considered high

Reducing Debt: PANG's debt to equity ratio has increased from 30.7% to 55.2% over the past 5 years.


Balance Sheet

Inventory Level: PANG has a low level of unsold assets or inventory.

Debt Coverage by Assets: PANG's debt is covered by short term assets (assets are 1.148140x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if PANG has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PANG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Pangaea Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%5.7%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PANG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PANG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PANG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PANG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PANG's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

What is the CEO of Pangaea Oncology's salary, the management and board of directors tenure and is there insider trading?


CEO

Javier Rivela-Rodriguez 0

0yrs

Tenure

0

Mr. Javier Rivela-Rodriguez, MBA, CFA, is a Co-Founder, Chief Executive Officer and Director of Pangaea Oncology, S.A. Mr. Rivela-Rodriguez served as Equity Analyst of Redwood Securities Group, Inc., Resea ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Javier Rivela-Rodriguez

    Co-Founder

    • Tenure: 0yrs
  • Rafael Rosell

    Co-Founder

    • Tenure: 0yrs
  • Santiago Ramon y Cajal

    Co-Founder

    • Tenure: 0yrs
  • Santiago Viteri

    Chief of Staff for IOR

    • Tenure: 0yrs
  • Carmen Albiol

    Head of Operations for IOR

    • Tenure: 0yrs
  • Quentin Buraglio

    Chief Financial Officer

    • Tenure: 0yrs
  • Miguel Angel Molina

    Director of Laboratory Technical & Member of Scientific Committee

    • Tenure: 0yrs
  • Andrea Sáez

    Director of Drug Development & Member of Scientific Committee

    • Tenure: 0yrs
  • Amparo Dávila

    Director of Diagnostics Business Development & Member of Scientific Committee

    • Tenure: 0yrs

Board Members

  • Javier Rivela-Rodriguez

    Co-Founder

    • Tenure: 0yrs
  • Jesús Tejel Giménez

    Independent Director

    • Tenure: 0yrs
  • Rafael Rosell

    Co-Founder

    • Tenure: 0yrs
  • Santiago Ramon y Cajal

    Co-Founder

    • Tenure: 0yrs
  • Jose Maestre

    Director

    • Tenure: 0yrs
  • Luis Barcelona

    Director

    • Tenure: 0yrs
  • Santiago Viteri

    Chief of Staff for IOR

    • Tenure: 0yrs
  • Miguel Angel Molina

    Director of Laboratory Technical & Member of Scientific Committee

    • Tenure: 0yrs
  • Andrea Sáez

    Director of Drug Development & Member of Scientific Committee

    • Tenure: 0yrs
  • Amparo Dávila

    Director of Diagnostics Business Development & Member of Scientific Committee

    • Tenure: 0yrs

Company Information

Pangaea Oncology, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pangaea Oncology, S.A.
  • Ticker: PANG
  • Exchange: BME
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €26.432m
  • Shares outstanding: 15.55m
  • Website: https://www.panoncology.com

Number of Employees


Location

  • Pangaea Oncology, S.A.
  • C/ Sabino Arana, 5-19
  • Barcelona
  • Catalonia
  • 8028
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PANGBME (Bolsas y Mercados Espanoles)YesShare CapitalESEURDec 2016

Biography

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation anal ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 21:59
End of Day Share Price2019/10/18 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.